Loading
A phase 2 trial of TQB2102 in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting.
A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer is a phase 2 interventional study registered as NCT06198751 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 104 participants enrolled, started 2024-02-05 and due to reach its primary completion in 2025-05-08. Interventions recorded: 6.0 mg/kg of TQB2102 for injection and 7.5 mg/kg of TQB2102 for injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/